A5068324675- Rheumatoid Arthritis Research and Therapies
- Chronic Lymphocytic Leukemia Research
- Transportation Planning and Optimization
- Lymphoma Diagnosis and Treatment
- Urban Transport and Accessibility
- Transportation and Mobility Innovations
- Retinal Diseases and Treatments
- Traffic Prediction and Management Techniques
- Systemic Lupus Erythematosus Research
- Retinal Imaging and Analysis
- Evacuation and Crowd Dynamics
- Retinal and Optic Conditions
- Peripheral Artery Disease Management
- Monoclonal and Polyclonal Antibodies Research
- Colorectal Cancer Treatments and Studies
- Human Mobility and Location-Based Analysis
- HER2/EGFR in Cancer Research
- Magnesium in Health and Disease
- Biosimilars and Bioanalytical Methods
- Lung Cancer Treatments and Mutations
- Parathyroid Disorders and Treatments
- Ophthalmology and Visual Impairment Studies
- Spatial and Panel Data Analysis
- Immunodeficiency and Autoimmune Disorders
- Cerebrovascular and Carotid Artery Diseases
Institute of Science Tokyo
2024
Astellas Pharma (United States)
2022-2023
Center for Global Development
2014-2023
Kyoto University
2023
Astellas Pharma (Japan)
2013-2022
Yamagata University
2020
Tokyo Medical and Dental University
2013-2020
Nihon University
2007-2019
Surugadai Nihon University Hospital
2014
Kanagawa Institute of Technology
2011
Abstract A number of preclinical studies have indicated the therapeutic potential endothelial progenitor cells for vascular regeneration in ischemic diseases. phase I/IIa clinical trial transplantation autologous CD34+ cells, and hematopoietic progenitor-enriched fraction, was performed no-option patients with atherosclerotic peripheral artery disease or Buerger's critical limb ischemia (CLI). were isolated from G-CSF-mobilized apheresis product using a magnetic cell sorting system. (105/kg,...
Objective To evaluate the efficacy, safety and dose response of a novel oral Janus kinase inhibitor, peficitinib (ASP015K), as monotherapy in Japanese patients with moderate to severe rheumatoid arthritis (RA). Methods In 12-week, double-blind study, 281 adult RA active disease not on concomitant disease-modifying antirheumatic drug therapy were randomised equally once-daily placebo or 25, 50, 100 150 mg. The primary endpoint was American College Rheumatology (ACR) 20 treatment groups versus...
Objective To evaluate the efficacy and safety of oral Janus kinase (JAK) inhibitor peficitinib versus placebo in Japanese patients with rheumatoid arthritis (RA). Methods In this multicentre, double-blind, parallel-group, placebo-controlled phase III study, RA inadequate response to methotrexate (MTX) were randomised 1:1:1 placebo, 100 mg once daily or 150 MTX for 52 weeks. Based on baseline randomisation, at week 12, non-responders receiving switched until end treatment; remaining 28....
To investigate the efficacy and safety of peficitinib, an oral Janus kinase inhibitor, in patients with rheumatoid arthritis (RA).In this double-blind phase III study, RA inadequate response to prior disease-modifying anti-rheumatic drugs (DMARDs) were randomised peficitinib 100 mg once daily, 150 placebo or open-label etanercept for 52 weeks' treatment; placebo-treated switched at week 12 daily. The primary endpoint was American College Rheumatology (ACR)20 12/early termination (ET)....
We investigated the vascular system in far peripheral retina eyes with pathologic myopia by ultra-widefield fluorescein angiography (FA).We analyzed retrospectively 230 (myopic refractive error >8 diopters [D] or axial length >26.5 mm) and 42 emmetropic (refractive < ± 2 D) controls who were examined FA Optos P200 system. Far was defined as area anterior to ampullae of vortex veins.Retinal capillary telangiectasia observed periphery 34 (81.0%) 90 115 (78.3%) highly myopic eyes. Retinal...
To investigate the 6-year outcome of intravitreal bevacizumab (IVB) to treat eyes with active choroidal neovascularization (CNV) due pathologic myopia.Medical records 36 35 consecutive patients high myopia (refractive error ≥8 D or axial length ≥26.5 mm) and CNV, who had been treated IVB followed for ≥6 years were analyzed. The factors that predicted best-corrected visual acuity (BCVA) at 6 after determined by multiple regression analyses.The mean age subjects was 58 years, 29 mm. Twenty-one...
It is common for physicians to be uncertain when examining some images. Models trained with human uncertainty could a help in diagnosing pathologic myopia.
Abstract Background Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety for the treatment of rheumatoid arthritis (RA) in randomized, controlled trials up to 52 weeks’ duration. However, effectiveness after long-term have not been assessed. Methods This was an interim analysis ongoing open-label, multicenter extension study RA patients who completed phase 2b (RAJ1; 12 weeks) 3 (RAJ3 RAJ4; peficitinib studies Asia (mainly Japan). Eligible ( n =...
Abstract Hyperphosphatemia is a prognostic factor for morbidity and mortality in chronic kidney disease. Bixalomer nonabsorbable polymer that decreases serum phosphate levels by binding the gastrointestinal tract. This study compared efficacy safety of bixalomer versus sevelamer hydrochloride controlling hyperphosphatemia hemodialysis patients. was multicenter, randomized open‐label, non‐inferiority study. The primary endpoint on completion treatment. Administration started at 1.5 g/day...
To determine the 5-year outcome of intravitreal ranibizumab (IVR) for myopic choroidal neovascularization (CNV).We retrospectively analyzed medical records 51 eyes consecutive patients with CNV who had been treated IVR a minimum follow-up period 5 years after initial injection. The factors that predicted best-corrected visual acuity (BCVA) at were determined by multiple regression analysis.The mean age subjects was 63.6 years, and axial length 29.4 mm. number 1.6, 34 (66.7%) only single IVR....
This final analysis of a long-term extension (LTE) study assessed the safety, tolerability, and effectiveness peficitinib (ASP015K), pan-Janus kinase inhibitor, in Asian patients with rheumatoid arthritis (RA). Patients had previously completed 12-week phase 2b (RAJ1), or 52-week 3 (RAJ3 RAJ4) studies Japan, Korea, Taiwan, received oral 50 100 mg/day. Dose increase to 150 mg/day reduction was permitted. Efficacy endpoints included American College Rheumatology (ACR)20/50/70 response rates,...
This study empirically analyzes the effects of urban railway investment on regional population density, employment and land price using spatial difference-in-differences (DID) approach, employing a sociodemographic socioeconomic dataset in 2,843 zones Tokyo Metropolitan Area from 2000 to 2010. A spatial-lag model spatial-error model, addition an ordinary least square under framework DID are employed empirical analyses. The results show that lines was areas with lower densities higher...
Peficitinib is an oral pan-Janus kinase inhibitor for the treatment of rheumatoid arthritis. Co-administration peficitinib with metformin, a type 2 diabetes therapy, can occur in clinical practice. Hepatic and renal uptake metformin mediated by organic cation transporter 1 (OCT1) OCT2, respectively, its excretion multidrug toxin extrusion (MATE1) MATE2-K. This study investigated effect on pharmacokinetics vitro healthy volunteers.Inhibitory effects metabolite H2 into human OCT1/2-...
Epidermal growth factor receptor (EGFR)-activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non-small-cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once-daily, oral, EGFR TKI that inhibits both activating and resistance mutations. This dose-escalation/dose-expansion study (NCT02192697) was undertaken in two phases. In phase I, Japanese patients (aged ≥20 years) with NSCLC previously treated ≥1 received escalating doses (25-600 mg)...
This study measured and compared the exposure safety of peficitinib (ASP015K), a novel oral Janus kinase inhibitor, in subjects with normal impaired renal function after single oral, clinically relevant dose.This was an open-label, parallel-group conducted at two centres Japan. Subjects mildly, moderately, or severely received dose (one 150 mg tablet) under fasting conditions hospital setting. Blood samples were collected prior to administration up 72 h post-dose for pharmacokinetic...
Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune condition characterized by joint synovial inflammation. Current treatments include methotrexate (MTX), biologic agents, and Janus kinase (JAK) inhibitors. However, these agents are not efficacious in all patients there concerns regarding side effects risk of infection as target immune-related pathways. Overexpression activation integrin alpha-9 (α9) on fibroblast-like synoviocytes associated with RA disease onset exacerbation....
Bixalomer is a nonabsorbable polymer that binds phosphate in the gastrointestinal tract and lowers serum level by inhibiting absorption. The safety efficacy of long-term bixalomer treatment were assessed Japanese hemodialysis patients with hyperphosphatemia. This was multicenter open-label study 48-week period. main endpoints rate achieving target range (3.5-6.0 mg/dL). initiated at dose 1.5 g/day, which increased to maximum 7.5 g/day depending on response. Of 248 subjects who started...
Abstract Peficitinib (ASP015K) is a novel Janus kinase inhibitor developed for the treatment of rheumatoid arthritis (RA). The impact hepatic impairment on peficitinib pharmacokinetic (PK) and safety profile was investigated in non‐RA subjects (n = 24) an open‐label, parallel‐group, multicenter comparative study Japan. Subjects received single, clinically relevant, oral dose 150 mg tablet under fasting conditions. Plasma PK parameters were measured its metabolites H1 (sulfate methylated...
Abstract The ability of clonal plants to spread horizontally and share resources within genets has long been considered advantageous in spatially heterogeneous environments, yet our understanding how such traits relate its widespread success dominance is still limited. Using a dwarf bamboo, Sasa kurilensis , that often dominates cool‐temperate forest understorys, we investigated population recovery over 20 years after an episodic die‐off may be augmented by expansion via rhizomes. Previous...
To evaluate the safety of peficitinib for treatment rheumatoid arthritis (RA) in Asian patients. Safety data from one Phase 2b, two 3, and open-label long-term extension study [data cut-off 31 May 2018] were pooled into 3 studies (peficitinib 100 150 mg/day, placebo) 2/3 (all peficitinib-treated patients). Incidence rates per patient-years (PY) adverse events (AEs) special interest calculated. Overall, 1052 patients received 2336.3 PY exposure (median 2.1 years); four deaths occurred,...
Abstract Hyperphosphatemia is a prognostic factor for morbidity and mortality in chronic kidney disease. Bixalomer ( K iklin ® C apsules) non‐absorbable polymer that decreases serum phosphate levels by binding the gastrointestinal tract. This study was multicenter, double‐blind, randomized, placebo‐controlled to confirm superiority of bixalomer placebo 4‐week treatment period patients with disease on hemodialysis hyperphosphatemia. Sevelamer hydrochloride HCl ), similar polymer, used as an...
Abstract Background Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety in the treatment of patients with rheumatoid arthritis (RA). This study evaluated effect peficitinib on patient- physician-reported outcomes Asian RA an inadequate response to prior disease-modifying antirheumatic drugs (DMARDs). Methods Patients from two randomized, placebo-controlled, double-blind, phase 3 trials (RAJ3 RAJ4) received once-daily 100 mg, 150 or placebo, alone...
Azathioprine (AZA) is increasingly being prescribed to rheumatoid arthritis (RA) patients. Following oral administration, AZA converted into its active form. Inflammatory bowel disease (IBD) and systemic lupus erythematosus (SLE) patients with low thiopurine (S)-methyltransferase (TPMT) activity tend respond well therapy. In a previous study of Japanese SLE under low-dose therapy, the group 94C>A mutation in inosine triphosphatase (ITPA) showed greater improvement their index. However, it...